JP2022523553A5 - - Google Patents

Info

Publication number
JP2022523553A5
JP2022523553A5 JP2021552599A JP2021552599A JP2022523553A5 JP 2022523553 A5 JP2022523553 A5 JP 2022523553A5 JP 2021552599 A JP2021552599 A JP 2021552599A JP 2021552599 A JP2021552599 A JP 2021552599A JP 2022523553 A5 JP2022523553 A5 JP 2022523553A5
Authority
JP
Japan
Prior art keywords
amino acid
tcr
eso
acid sequence
constant region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021552599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523553A (ja
JP7748284B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/051809 external-priority patent/WO2020178740A1/en
Publication of JP2022523553A publication Critical patent/JP2022523553A/ja
Publication of JP2022523553A5 publication Critical patent/JP2022523553A5/ja
Application granted granted Critical
Publication of JP7748284B2 publication Critical patent/JP7748284B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021552599A 2019-03-04 2020-03-03 T細胞受容体及びその使用方法 Active JP7748284B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813644P 2019-03-04 2019-03-04
US62/813,644 2019-03-04
PCT/IB2020/051809 WO2020178740A1 (en) 2019-03-04 2020-03-03 T cell receptors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022523553A JP2022523553A (ja) 2022-04-25
JP2022523553A5 true JP2022523553A5 (cg-RX-API-DMAC7.html) 2023-03-13
JP7748284B2 JP7748284B2 (ja) 2025-10-02

Family

ID=72337471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552599A Active JP7748284B2 (ja) 2019-03-04 2020-03-03 T細胞受容体及びその使用方法

Country Status (13)

Country Link
US (1) US12527809B2 (cg-RX-API-DMAC7.html)
EP (1) EP3935175A4 (cg-RX-API-DMAC7.html)
JP (1) JP7748284B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210149049A (cg-RX-API-DMAC7.html)
CN (1) CN113795583B (cg-RX-API-DMAC7.html)
AU (1) AU2020231693A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017491A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132242A1 (cg-RX-API-DMAC7.html)
IL (1) IL286039A (cg-RX-API-DMAC7.html)
MX (1) MX2021010542A (cg-RX-API-DMAC7.html)
SG (1) SG11202109590VA (cg-RX-API-DMAC7.html)
TW (1) TW202100547A (cg-RX-API-DMAC7.html)
WO (1) WO2020178740A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021010537A (es) 2019-03-04 2021-12-10 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
AU2020231927A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
US12522644B2 (en) 2019-03-04 2026-01-13 University Health Network T cell receptors and methods of use thereof
AU2020231693A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
CA3133945A1 (en) 2019-03-25 2020-10-01 University Health Network T cell receptors and methods of use thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323632A1 (en) 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
CA2682093A1 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
EP3031916B1 (en) 2007-06-11 2017-06-07 Takara Bio Inc. Method for expression of specific gene
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010112962A1 (en) 2009-04-02 2010-10-07 Vaxon Biotech Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy
US9314516B2 (en) * 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
ES2635335T3 (es) 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
ES2924709T3 (es) 2014-10-02 2022-10-10 Us Health Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer
CA2964785A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
CN106632658B (zh) * 2015-11-04 2020-10-27 广东香雪精准医疗技术有限公司 识别ny-eso-1抗原短肽的tcr
JP6895975B2 (ja) 2016-01-06 2021-06-30 ヘルス リサーチ インコーポレイテッドHealth Research, Inc. 組換えt細胞受容体を含む組成物及びライブラリー並びに組換えt細胞受容体を使用する方法
JP2019521080A (ja) 2016-04-27 2019-07-25 ユニバーシティ・ヘルス・ネットワーク ペプチド−hla複合体およびその産生方法
AU2017356322B2 (en) * 2016-11-14 2023-09-21 Fred Hutchinson Cancer Center High affinity merkel cell polyomavirus T antigen-specific TCRs and uses thereof
JP7289028B2 (ja) * 2018-09-05 2023-06-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 複数の主要組織適合遺伝子複合体分子に制限したny-eso-1-特異的t細胞受容体の組成物
AU2020231927A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
BR112021017404A2 (pt) 2019-03-04 2022-02-01 Univ Health Network Receptores de células t e métodos de uso dos mesmos
MX2021010537A (es) 2019-03-04 2021-12-10 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
EP3935173A4 (en) 2019-03-04 2023-05-31 University Health Network T-CELL RECEPTORS AND METHODS OF USE THEREOF
AU2020231693A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
CA3132434A1 (en) 2019-03-04 2020-09-10 University Health Network T cell receptors and methods of use thereof
US12522644B2 (en) 2019-03-04 2026-01-13 University Health Network T cell receptors and methods of use thereof
CA3133945A1 (en) 2019-03-25 2020-10-01 University Health Network T cell receptors and methods of use thereof
TW202116797A (zh) 2019-07-30 2021-05-01 大學健康網絡 Ii類mhc分子及其使用方法
MX2022001206A (es) 2019-07-30 2022-05-03 Univ Health Network Receptores de linfocitos t y metodos de uso de los mismos.
AU2020320129A1 (en) 2019-07-30 2022-03-03 University Health Network T cell receptors and methods of use thereof
KR20220052944A (ko) 2019-07-30 2022-04-28 유니버시티 헬스 네트워크 Mhc 클래스 ii 분자 및 이의 사용 방법
TWI881991B (zh) 2019-07-30 2025-05-01 大學健康網絡 Ii類mhc分子及其使用方法
US20220291215A1 (en) 2019-07-30 2022-09-15 University Health Network Methods of identifying t cell receptors
WO2021019472A1 (en) 2019-07-30 2021-02-04 University Health Network T cell receptors and methods of use thereof
WO2023076875A1 (en) * 2021-10-25 2023-05-04 The Regents Of The University Of California Methods and compositions for treating glioblastoma

Similar Documents

Publication Publication Date Title
JP2022527267A5 (cg-RX-API-DMAC7.html)
JP2022523552A5 (cg-RX-API-DMAC7.html)
JP2022524993A5 (cg-RX-API-DMAC7.html)
JP2022523971A5 (cg-RX-API-DMAC7.html)
JP2022524994A5 (cg-RX-API-DMAC7.html)
JP2022523554A5 (cg-RX-API-DMAC7.html)
JP2022524992A5 (cg-RX-API-DMAC7.html)
CN113286811B (zh) 改善过继性细胞疗法的效力和安全性
Baxevanis et al. Cancer immunotherapy
Batlevi et al. Novel immunotherapies in lymphoid malignancies
Kershaw et al. Gene-engineered T cells for cancer therapy
JP2022543059A5 (cg-RX-API-DMAC7.html)
US20200038443A1 (en) Multi-function and multi-targeting car system and methods for use thereof
Merhavi-Shoham et al. Adoptive cell therapy for metastatic melanoma
CN109694854B (zh) 通用型嵌合抗原受体t细胞制备技术
JP2020509767A5 (cg-RX-API-DMAC7.html)
Tsang et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen.
Shilyansky et al. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
Junghans The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
US20170232070A1 (en) Combination Methods for Immunotherapy
Murad et al. Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies
CN113785065B (zh) T细胞受体及其使用方法
CN108138148A (zh) T细胞的激活和扩增
CN107847585A (zh) 用于得到体内存留性和治疗活性的nkt细胞亚群以及其繁殖
JP2022543060A5 (cg-RX-API-DMAC7.html)